Phuturdex › Diseases › Acromegaly
Drugs in development · updated 5 November 2026
Acromegaly: drugs in development
What it is
A rare acquired endocrine disease related to excessive production of growth hormone (GH) and characterized by progressive somatic disfigurement (mainly involving the face and extremities) and systemic manifestations.
Source: Orphanet, “Acromegaly” (ORPHA:963), www.orpha.net · licence CC BY 4.0 · Orphadata data of 23 June 2026.
As of 5 November 2026 there are 4 active clinical trials (recruiting or ongoing, phases I–III) on 3 drugs for acromegaly. 3 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 5 November 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Debio 4126 | III | 1 | NCT06930625 |
| MAR002 | II | 2 | NCT07641179 |
| NTQ6179 | I | 1 | NCT07909837 |
Sorted by most advanced phase and number of active trials.
All 3 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Broader categories
- Endocrine system disease 1,111 drugs
- Musculoskeletal disorder 451 drugs
- Central nervous system disease 978 drugs
- Nervous System Diseases 1,473 drugs
- Brain Diseases 849 drugs
- Bone disease 153 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 5 November 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D000172 “Acromegaly”. Prevalence: Orphanet.